Icatibant was investigated for treating ACE inhibitor–associated angioedema but was shown to lack clinical utility.
Icatibant is not effective for treating ACE inhibitor–induced angioedema.
Source: DDInter
Hemostatic · Drugs Used in Hereditary Angioedema
Also known as HOE-140, Firazyr, Icatibant acetate
Icatibant is a selective bradykinin B2 receptor antagonist. It blocks signaling mediated by B2 receptors, which can be activated by kinin generation or directly by certain proteases like kallikrein.
Manufacturer advises use only if potential benefit outweighs risk—toxicity in animal studies.
Manufacturer advises avoid for 12 hours after administration.
Icatibant was investigated for treating ACE inhibitor–associated angioedema but was shown to lack clinical utility.
Icatibant is not effective for treating ACE inhibitor–induced angioedema.
Source: DDInter
Icatibant was investigated for treating ACE inhibitor–associated angioedema but was shown to lack clinical utility.
Icatibant is not effective for treating ACE inhibitor–induced angioedema.
Source: DDInter
Icatibant was investigated for treating ACE inhibitor–associated angioedema but was shown to lack clinical utility.
Icatibant is not effective for treating ACE inhibitor–induced angioedema.
Source: DDInter
Icatibant was investigated for treating ACE inhibitor–associated angioedema but was shown to lack clinical utility.
Icatibant is not effective for treating ACE inhibitor–induced angioedema.
Source: DDInter
Icatibant was investigated for treating ACE inhibitor–associated angioedema but was shown to lack clinical utility.
Icatibant is not effective for treating ACE inhibitor–induced angioedema.
Source: DDInter
Icatibant was investigated for treating ACE inhibitor–associated angioedema but was shown to lack clinical utility.
Icatibant is not effective for treating ACE inhibitor–induced angioedema.
Source: DDInter
Icatibant was investigated for treating ACE inhibitor–associated angioedema but was shown to lack clinical utility.
Icatibant is not effective for treating ACE inhibitor–induced angioedema.
Source: DDInter
Icatibant was investigated for treating ACE inhibitor–associated angioedema but was shown to lack clinical utility.
Icatibant is not effective for treating ACE inhibitor–induced angioedema.
Source: DDInter
Icatibant was investigated for treating ACE inhibitor–associated angioedema but was shown to lack clinical utility.
Icatibant is not effective for treating ACE inhibitor–induced angioedema.
Source: DDInter
Icatibant was investigated for treating ACE inhibitor–associated angioedema but was shown to lack clinical utility.
Icatibant is not effective for treating ACE inhibitor–induced angioedema.
Source: DDInter
Icatibant was investigated for treating ACE inhibitor–associated angioedema but was shown to lack clinical utility.
Icatibant is not effective for treating ACE inhibitor–induced angioedema.
Source: G&G 14e
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: KD Tripathi 7e, Goodman & Gilman 14e, Katzung, BNF·Verified: 2026-05-10 · House clinical team